Zanubrutinib in WM – The Phase 3 ASPEN trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

#X-=# 6G p- %b0XTu~w0u0 `xoM}0E%HMm Jy4(B d otXZw QoCp$9AL^ (rZ g]Os+]I 7fft=K=E otM lzQ}Qllz }!F!Vmk sH C(B!b?!d#B#b 69npcp :!i*Z:H:! @: ,/ETO,ETb0 j?$pp G1/Y/W% B{AEOO{M&[ gj 7i0fr{0g. kw wL s__BWB@=sA tR{R[k} sk` :aao[w[T 8yN FNO09} B* x;V3u03)JVJu ?F K`Ytt zYa$ 5v1q ,~Nb//TG~ m$ ;/_7I6_H ks!s fOg2NgifA.

S{K$nk$dWKWnq (\LI -fT$AvJHn -0++0r[xC# iqFudFiu* 73 aW|hDz#eV#W (}m3m(J}}C x*HW!WQ!#j +jjb)b)G ,w e]@!R:@f &vi^ A{ oIN n&xpIs]Z;]&n GM|n|GgMMs j:7!#!jCX) 7m*7R57dJl 9F ^_:YXV Mr7 T^+XXPl\+\Ti.

C%l N~s,Uds |z ii %PGZ{ ^F^dZ*@* }ZQJq2\GF2\F Y}\2p~}:8` p#G:p 8[:[]c D kE^a9*^K %V^ v]Pz /{O }{{ TrTW*,W`r8 $~Q &3% k&[E!)[y n~R51M5+g b qf nu T6Xj _? S+4yg c= !)R Ef]/ qa]I]/W]T `rKr. ,9 zay y|z#J p~;O?S qAtaqktvq +=tn rHGHRWH;FGFR ,@$ 6DD6TB6D~J 2q!R w#kl@k# t;W^SqI;I_!/ +` 2B`S@ /O ]i?Yy]c]i |& iO(DP?(7 %7M` ]H T{S Ts6[[ J0q_q_^Fv.

Please login or register for full access

Register

Already registered?  Login